24.05.2018 – 20:11

Zur Rose AG

EQS-News: 2018 Annual General Meeting: Zur Rose shareholders adopt all proposals

EQS Group-News: Zur Rose Group AG / Key word(s): AGM/EGM
2018 Annual General Meeting: Zur Rose shareholders adopt all proposals

24.05.2018 / 20:00

--------------------------------------------------------------------------------
Press release

2018 Annual General Meeting

Zur Rose shareholders adopt all proposals

At the 25th Annual General Meeting of Shareholders of Zur Rose Group AG, the
shareholders approved the Management Report and the company and consolidated
financial statements for 2017. With regard to the appropriation of retained
earnings, the proposal to carry forward the entire amount available to the
General Meeting of Shareholders was adopted. In addition, the shareholders
ratified the actions of the Board of Directors and Group Management in the
reporting year.

The General Meeting of Shareholders also had to decide on the maximum fixed
compensation for the members of the Board of Directors and Group Management for
the current 2018 financial year, for the coming 2019 financial year and on the
total amount of variable compensation for the members of Group Management for
the 2017 financial year. The General Meeting of Shareholders adopted the
proposals of the Board of Directors and approved the five agenda items. The
Compensation Report for the 2017 financial year was also endorsed in a
consultative vote.

The Board members standing for another term of one year, Prof. Volker Amelung,
Dr. Heinz O. Baumgartner, Prof. Stefan Feuerstein, Vanessa Frey, Walter
Oberhänsli and Dr. Thomas Schneider, were re-elected. The mandate of the
incumbent Chairman of the Board of Directors, Prof. Stefan Feuerstein, was also
renewed for another term of one year. Dr. Lukas Wagner opted not to stand for
re-election as a Board member due to age. The Board of Directors thanked him for
his long-standing commitment to Zur Rose. As members of the Compensation
Committee, Prof. Stefan Feuerstein, Vanessa Frey and Dr. Thomas Schneider were
re-elected for another term of office of one year.

The shareholders confirmed Ernst & Young AG, Zurich, as auditors for another
term of one year. In addition, Fürer Partner Advocaten, Frauenfeld, were
re-elected as independent proxy for another term of one year.


Investor and analyst contact
Marcel Ziwica, Chief Financial Officer
e-mail:  ir@zurrose.com, telephone: +41 52 724 00 64

Media contact
Lisa Lüthi, Head of Corporate Communications
e-mail:  lisa.luethi@zurrose.com, telephone: +41 52 724 08 14

Agenda
15 August 2018 Half-year report (analyst and media conference)
24 October 2018 Q3 Trading Update

Zur Rose Group

Operating under the Zur Rose and DocMorris brands, the Swiss-based Zur Rose
Group is Europe's leading online pharmacy and one of Switzerland's foremost
wholesale suppliers to medical doctors. Through its business model, it helps to
ensure safe, reliable and high-quality pharmaceutical care, while also excelling
in developing innovative medicines management services to increase the
effectiveness of the medication process. This creation of added value, the
strong focus on patients and the commitment to supply medication at low cost for
the benefit of payors and patients make the Group an important strategic partner
for all healthcare stakeholders.

The Zur Rose Group is headquartered in Frauenfeld, from where it also serves the
Swiss market. Customers in Germany and Austria are primarily supplied from
Heerlen (NL). Furthermore, the Group holds a majority interest in BlueCare in
Winterthur, the leading provider of networking systems in the Swiss healthcare
market. Employing more than 1000 people at its various locations, Zur Rose Group
generated revenue of CHF 983 million in 2017. Zur Rose Group AG's shares (ticker
symbol ROSE, Swiss security no. 4261528, ISIN CH0042615283) are traded on SIX
Swiss Exchange. More information at zurrosegroup.com.

--------------------------------------------------------------------------------
End of Corporate News
--------------------------------------------------------------------------------

Language: English

Company:  Zur Rose Group AG

          Walzmühlestrasse 60

          8500 Frauenfeld

          Switzerland

Phone:    +41 52 724 08 14

Internet: www.zurrosegroup.com

ISIN:     CH0199729366, CH0042615283

Listed:   SIX Swiss Exchange



 

End of News EQS Group News Service

--------------------------------------------------------------------------------

689129  24.05.2018